Stocks
I
TMO I
Apr 24, 2024, 11:43:50 AM
Thermo Fisher Scientific Reports Solid Start to 2024 with First Quarter Financial Results
WALTHAM, Mass., April 24, 2024 – Thermo Fisher Scientific Inc. (NYSE: TMO), a global leader in serving science, today announced its financial outcomes for the first quarter ended March 30, 2024, revealing a consistent performance with several strategic advancements.
Financial Highlights
- First Quarter Revenue: The company recorded revenues of $10.34 billion.
- Earnings Per Share (EPS): GAAP diluted EPS saw a 4% increase, rising to $3.46. Meanwhile, adjusted EPS also grew by 2%, reaching $5.11.
Strategic Developments and Product Launches
Thermo Fisher has launched several high-impact products this quarter, underscoring its commitment to innovation:
- Thermo Scientific™ Dionex™ Inuvion™ Ion Chromatography System: Delivers higher resolution and faster results for water contaminant identification.
- Thermo Scientific™ LInspector™ Edge In-line Mass Profilometer: Aims to enhance battery safety and performance.
- Thermo Scientific™ TruScan™ G3 Handheld Raman Analyzer: A next-generation device for rapid chemical identification in drug production.
- Axiom™ PangenomiX Array: A high-throughput array designed for large-scale human genomic studies.
Enhancements in Customer Relationships and Services
The company has strengthened its commercial engine and deepened customer relationships:
- Launched the CorEvitas syndicated clinical registry for generalized pustular psoriasis.
- Expanded biosafety testing capabilities at the GMP lab in Middleton, Wisconsin.
- Developed next-generation sequencing-based companion diagnostics for precision cancer therapies.
Capital Management
Thermo Fisher remains aggressive in its capital deployment:
- Repurchased $3.0 billion of stock.
- Increased dividends by 11%.
Executive Commentary
Marc N. Casper, chairman, president, and CEO of Thermo Fisher, expressed satisfaction with the quarter's results, attributing the success to robust commercial execution and disciplined operational management.
Financial Performance Overview
- Revenue Decline: A 3% decrease from the $10.71 billion reported in the same period last year.
- Organic and Core Organic Revenue: Saw decreases of 4% and 3%, respectively.
- GAAP and Adjusted Operating Income: GAAP operating income grew, and adjusted operating margins saw a slight increase.
2024 Outlook
- Revenue Guidance: Raised to a range of $42.3 to $43.3 billion.
- Adjusted EPS Guidance: Now expected to be between $21.14 and $22.02.